Abbisko Cayman's (HKG:2256) unit, Abbisko Therapeutics, reported "positive top-line results" for its Phase 3 MANEUVER study of pimicotinib after the study met primary endpoint with a response rate of 54% at week 25 compared with 3.2% for placebo, according to a Tuesday filing with the Hong Kong bourse.
Pimicotinib, a small molecule inhibitor of CSF-1R, has shown positive results in patients with tenosynovial giant cell tumor, the filing said.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。